{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:29:05Z","timestamp":1771666145848,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.ajo.2004.10.005","type":"journal-article","created":{"date-parts":[[2005,1,29]],"date-time":"2005-01-29T07:22:16Z","timestamp":1106983336000},"page":"421-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["The safety profile of long-term, high-dose intraocular corticosteroid delivery"],"prefix":"10.1016","volume":"139","author":[{"given":"Nancy M.","family":"Holekamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2004.10.005_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1442-9071.1998.tb01330.x","article-title":"Exudative macular degeneration and intravitreal triamcinolone","volume":"26","author":"Challa","year":"1998","journal-title":"Aust N Z J Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00006982-200003000-00004","article-title":"Intravitreal triamcinolone acetonide in exudative age-related macular degeneration","volume":"20","author":"Danis","year":"2000","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2004.10.005_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bjo.86.5.527","article-title":"Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularization after laser treatment in macular degeneration","volume":"86","author":"Ranson","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archopht.121.5.667","article-title":"A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration","volume":"121","author":"Gillies","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archopht.121.9.1279","article-title":"Noninfectious endophthalmitis associated with intravitreal triamcinolone injection","volume":"121","author":"Roth","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9394(03)00389-1","article-title":"Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome","volume":"136","author":"Rechtman","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00417-001-0398-y","article-title":"Inhibitory effets of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells","volume":"240","author":"Wang","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000050875","article-title":"Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro","volume":"215","author":"Kaven","year":"2001","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ajo.2004.10.005_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0014-2999(97)01464-7","article-title":"Corticosteroids inhibit the expression of vascular endothelial growth factor gene in human vascular smooth muscle cells","volume":"341","author":"Nauck","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ajo.2004.10.005_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archopht.119.3.399","article-title":"Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model","volume":"119","author":"Ciulla","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib11","first-page":"S172","article-title":"Intravitreal sustained release fluocinolone implant inhibits experimental choroidal neovascularization","volume":"40S","author":"Taba","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2004.10.005_bib12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/jop.1994.10.691","article-title":"Review","volume":"10","author":"Ashton","year":"1994","journal-title":"J Ocul Pharmacol"},{"key":"10.1016\/j.ajo.2004.10.005_bib13","first-page":"3569","article-title":"Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device","volume":"41","author":"Jaffe","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2004.10.005_bib14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archopht.1994.01090240037023","article-title":"Treatment of cytomegalovirus retinitis with an intraocular sustained release ganciclovir implant. A randomized clinical trial","volume":"112","author":"Martin","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib15","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0161-6420(00)00466-8","article-title":"Fluocinolone acetonide sustained drug delivery device to treat severe uveitis","volume":"107","author":"Jaffe","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2004.10.005_bib16","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0161-6420(94)31172-9","article-title":"Visual results after surgical removal of subfoveal choroidal neovascular membranes","volume":"101","author":"Thomas","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2004.10.005_bib17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0161-6420(92)31869-X","article-title":"Clinical experience with surgical removal of subfoveal neovascular membranes","volume":"99","author":"Berger","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2004.10.005_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9394(14)72951-4","article-title":"Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes","volume":"118","author":"Gass","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2004.10.005_bib19","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0161-6420(95)30844-5","article-title":"Nuclear sclerotic cataract after vitrectomy in patients under 50 years of age","volume":"102","author":"Melberg","year":"1995","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939404012413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939404012413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:48:30Z","timestamp":1757594910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939404012413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0002939404012413"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2004.10.005","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety profile of long-term, high-dose intraocular corticosteroid delivery","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2004.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}